Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Minimal Residual Disease in Autografts and Bone Marrow of Patients with Multiple Myeloma: 8-Color Multiparameter Flow Cytometry (EuroFlow-NGF) Vs . Next-Generation Sequencing

Hiroyuki Takamatsu, MDPhD, Naoki Takezako, MDPhD, Takeshi Yoroidaka, MD, Takeshi Yamashita, MD, Ryoichi Murata, MD, Atsuko Yamazaki, MD, Masahiro Takeuchi, MD PhD, Naoya Mimura, MD PhD, Chiaki Nakaseko, MD PhD, Emiko Sakaida, MDPhD, Masahiro Onoda, MD, Yoshikazu Utsu, MD PhD, Motoharu Fukazawa, MD, Kosei Matsue, MDPhD, Shinji Nakao, MD PhD

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-137014

Published: 2020

Journal Articles

Minimal Residual Disease Assessment Using Euroflow-NGF in Patients with Multiple Myeloma Treated with a Combination of Carfilzomib, Lenalidomide, and Dexamethasone (KRD)

Takeshi Yoroidaka, MD, Hiroyuki Takamatsu, MD PhD, Takeshi Yamashita, MD, Ryoichi Murata, MD, Kyoko Yoshihara, MD PhD, Satoshi Yoshihara, MD PhD, Mikio Ueda, MD PhD, Shinji Nakao, MD PhD, Kosei Matsue, MD PhD

Blood (2019) 134 (Supplement_1): 3130.

https://doi.org/10.1182/blood-2019-126552

Published: 2019

Journal Articles

Comparison of Minimal Residual Disease Detection between the Manual and Automated Gating Strategies of Euroflow Next-Generation Flow in Patients with Multiple Myeloma

Hiroyuki Takamatsu, MD PhD, Takeshi Yoroidaka, MD, Takeshi Yamashita, MD, Ryoichi Murata, MD, Mikio Ueda, MD PhD, Shinji Nakao, MD PhD, Kosei Matsue, MD PhD

Blood (2019) 134 (Supplement_1): 3083.

https://doi.org/10.1182/blood-2019-122398

Published: 2019

Journal Articles

Comparison of Minimal Residual Disease Detection in Autografts of Patients with Multiple Myeloma between 8-Color Multiparameter Flow Cytometry (EuroFlow) and Next-Generation Sequencing

Hiroyuki Takamatsu, MDPhD, Naoki Takezako, MD PhD, Rachel K Wee, Takeshi Yoroidaka, MD, Takeshi Yamashita, MD, Ryoichi Murata, MD, Kosei Matsue, MD PhD, Shinji Nakao, MD PhD

Blood (2018) 132 (Supplement 1): 258.

https://doi.org/10.1182/blood-2018-99-111250

Published: 2018

Journal Articles

Prognostic Value of Sequencing-Based Minimal Residual Disease Detection in Patients with Multiple Myeloma Who Underwent Autologous Stem Cell Transplantation

Hiroyuki Takamatsu, Ryoichi Murata, MD, Jianbiao Zheng, Martin Moorhead, Naoki Takezako, Shigeki Ito, MD PhD, Toshihiro Miyamoto, MD PhD, Kenji Yokoyama, Kosei Matsue, MD PhD, Tsutomu Sato, MD PhD, Toshiro Kurokawa, MD PhD, Hideo Yagi, Yasushi Terasaki, MD PhD, Kinya Ohata, MD PhD, Takashi Yoshida, MD PhD, Malek Faham, MD PhD, Shinji Nakao, MD PhD

Blood (2015) 126 (23): 1788.

https://doi.org/10.1182/blood.V126.23.1788.1788

Published: 2015

Journal Articles

A Comparison of Minimal Residual Disease Detection Among ASO-PCR, Dd-PCR and Deep-Sequencing in Patients with Multiple Myeloma Who Underwent Autologous Stem Cell Transplantation

Rachel K Wee, Hiroyuki Takamatsu, MD PhD, Ryoichi Murata, MD, Jianbiao Zheng, PhD, Martin Moorhead, PhD, Naoki Takezako, MD PhD, Shigeki Ito, MD PhD, Toshihiro Miyamoto, MD PhD, Kenji Yokoyama, MD PhD, Kosei Matsue, MD PhD, Tsutomu Sato, MD PhD, Toshiro Kurokawa, MD PhD, Hideo Yagi, MD PhD, Yasushi Terasaki, MD PhD, Kinya Ohata, MD PhD, Takashi Yoshida, MD PhD, Malek Faham, MD PhD, Shinji Nakao, MD PhD

Blood (2015) 126 (23): 1782.

https://doi.org/10.1182/blood.V126.23.1782.1782

Published: 2015

Journal Articles

Prognostic Value of Sequencing-Based Minimal Residual Disease Detection in Multiple Myeloma

Hiroyuki Takamatsu, MD PhD, Ryoichi Murata, MD, Jianbiao Zheng, PhD, Martin Moorhead, PhD, Naoki Takezako, MD PhD, Shigeki Ito, MD, PhD, Toshihiro Miyamoto, MD PhD, Kenji Yokoyama, MD PhD, Kosei Matsue, MD PhD, Tsutomu Sato, MD PhD, Toshiro Kurokawa, MD PhD, Hideo Yagi, MD PhD, Yasushi Terasaki, MD PhD, Kinya Ohata, MD PhD, Takashi Yoshida, MD PhD, Malek Faham, MD PhD, Shinji Nakao, MD PhD

Blood (2014) 124 (21): 2003.

https://doi.org/10.1182/blood.V124.21.2003.2003

Published: 2014

NARROW

Minimal Residual Disease in Autografts and Bone Marrow of Patients with Multiple Myeloma: 8-Color Multiparameter Flow Cytometry (EuroFlow-NGF) Vs . Next-Generation Sequencing

Minimal Residual Disease Assessment Using Euroflow-NGF in Patients with Multiple Myeloma Treated with a Combination of Carfilzomib, Lenalidomide, and Dexamethasone (KRD)

Comparison of Minimal Residual Disease Detection between the Manual and Automated Gating Strategies of Euroflow Next-Generation Flow in Patients with Multiple Myeloma

Comparison of Minimal Residual Disease Detection in Autografts of Patients with Multiple Myeloma between 8-Color Multiparameter Flow Cytometry (EuroFlow) and Next-Generation Sequencing

Prognostic Value of Sequencing-Based Minimal Residual Disease Detection in Patients with Multiple Myeloma Who Underwent Autologous Stem Cell Transplantation

A Comparison of Minimal Residual Disease Detection Among ASO-PCR, Dd-PCR and Deep-Sequencing in Patients with Multiple Myeloma Who Underwent Autologous Stem Cell Transplantation

Prognostic Value of Sequencing-Based Minimal Residual Disease Detection in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Minimal Residual Disease in Autografts and Bone Marrow of Patients with Multiple Myeloma: 8-Color Multiparameter Flow Cytometry (EuroFlow-NGF) Vs . Next-Generation Sequencing

Minimal Residual Disease Assessment Using Euroflow-NGF in Patients with Multiple Myeloma Treated with a Combination of Carfilzomib, Lenalidomide, and Dexamethasone (KRD)

Comparison of Minimal Residual Disease Detection between the Manual and Automated Gating Strategies of Euroflow Next-Generation Flow in Patients with Multiple Myeloma

Comparison of Minimal Residual Disease Detection in Autografts of Patients with Multiple Myeloma between 8-Color Multiparameter Flow Cytometry (EuroFlow) and Next-Generation Sequencing

Prognostic Value of Sequencing-Based Minimal Residual Disease Detection in Patients with Multiple Myeloma Who Underwent Autologous Stem Cell Transplantation

A Comparison of Minimal Residual Disease Detection Among ASO-PCR, Dd-PCR and Deep-Sequencing in Patients with Multiple Myeloma Who Underwent Autologous Stem Cell Transplantation

Prognostic Value of Sequencing-Based Minimal Residual Disease Detection in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only